Arovella Therapeutics Ltd
Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, … Read more
Arovella Therapeutics Ltd (ALA) - Total Assets
Latest total assets as of December 2025: AU$20.25 Million AUD
Based on the latest financial reports, Arovella Therapeutics Ltd (ALA) holds total assets worth AU$20.25 Million AUD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Arovella Therapeutics Ltd - Total Assets Trend (2001–2025)
This chart illustrates how Arovella Therapeutics Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Arovella Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Arovella Therapeutics Ltd's total assets of AU$20.25 Million consist of 98.0% current assets and 2.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$20.88 Million | 96.7% |
| Accounts Receivable | AU$0.00 | 0.0% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$430.57K | 2.0% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Arovella Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arovella Therapeutics Ltd's current assets represent 98.0% of total assets in 2025, an increase from 71.0% in 2001.
- Cash Position: Cash and equivalents constituted 96.7% of total assets in 2025, up from 70.7% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 28.0% in 2001.
- Asset Diversification: The largest asset category is cash and equivalents at 96.7% of total assets.
Arovella Therapeutics Ltd Competitors by Total Assets
Key competitors of Arovella Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Arovella Therapeutics Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Arovella Therapeutics Ltd generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Arovella Therapeutics Ltd is currently not profitable relative to its asset base.
Arovella Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.36 | 11.24 | 3.79 |
| Quick Ratio | 15.36 | 11.24 | 3.78 |
| Cash Ratio | 0.00 | 10.82 | 3.60 |
| Working Capital | AU$18.55 Million | AU$ 11.12 Million | AU$ 4.24 Million |
Arovella Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Arovella Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.79 |
| Latest Market Cap to Assets Ratio | 1.84 |
| Asset Growth Rate (YoY) | 62.6% |
| Total Assets | AU$21.60 Million |
| Market Capitalization | $39.76 Million USD |
Valuation Analysis
Above Book Valuation: The market values Arovella Therapeutics Ltd's assets above their book value (1.84 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Arovella Therapeutics Ltd's assets grew by 62.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Arovella Therapeutics Ltd (2001–2025)
The table below shows the annual total assets of Arovella Therapeutics Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$21.60 Million | +62.60% |
| 2024-06-30 | AU$13.28 Million | +142.82% |
| 2023-06-30 | AU$5.47 Million | -40.61% |
| 2022-06-30 | AU$9.21 Million | -13.80% |
| 2021-06-30 | AU$10.69 Million | +59.33% |
| 2020-06-30 | AU$6.71 Million | -58.73% |
| 2019-06-30 | AU$16.25 Million | -2.34% |
| 2018-06-30 | AU$16.64 Million | -16.85% |
| 2017-06-30 | AU$20.02 Million | +2.56% |
| 2016-06-30 | AU$19.52 Million | -14.48% |
| 2015-06-30 | AU$22.82 Million | +12.16% |
| 2014-06-30 | AU$20.35 Million | +89.65% |
| 2013-06-30 | AU$10.73 Million | +9.99% |
| 2012-06-30 | AU$9.75 Million | -27.88% |
| 2011-06-30 | AU$13.53 Million | +13.64% |
| 2010-06-30 | AU$11.90 Million | -28.35% |
| 2009-06-30 | AU$16.61 Million | +3.41% |
| 2008-06-30 | AU$16.06 Million | -23.50% |
| 2007-06-30 | AU$21.00 Million | +26.27% |
| 2006-06-30 | AU$16.63 Million | +11.22% |
| 2005-06-30 | AU$14.95 Million | -7.11% |
| 2004-06-30 | AU$16.10 Million | +245.95% |
| 2003-06-30 | AU$4.65 Million | +47.97% |
| 2002-06-30 | AU$3.14 Million | -48.60% |
| 2001-06-30 | AU$6.12 Million | -- |